173 related articles for article (PubMed ID: 27739365)
1. EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo.
Zhou C; Zhu L; Ji J; Ding F; Wang C; Cai Q; Yu Y; Zhu Z; Zhang J
Curr Cancer Drug Targets; 2017; 17(1):89-97. PubMed ID: 27739365
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.
Shi M; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Curr Cancer Drug Targets; 2014; 14(2):217-24. PubMed ID: 24467518
[TBL] [Abstract][Full Text] [Related]
3. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
5. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
6. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
[TBL] [Abstract][Full Text] [Related]
7. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
[TBL] [Abstract][Full Text] [Related]
8. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.
Zhao L; He LR; Xi M; Cai MY; Shen JX; Li QQ; Liao YJ; Qian D; Feng ZZ; Zeng YX; Xie D; Liu MZ
J Transl Med; 2012 Dec; 10():249. PubMed ID: 23232108
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
10. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
[TBL] [Abstract][Full Text] [Related]
11. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
Bhuvaneswari R; Ng QF; Thong PS; Soo KC
Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
13. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
15. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
[TBL] [Abstract][Full Text] [Related]
16. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of
Tikum AF; Ketchemen JP; Doroudi A; Nambisan AK; Babeker H; Njotu FN; Fonge H
J Nucl Med; 2024 Feb; ():. PubMed ID: 38360051
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells.
Assi M; Achouri Y; Loriot A; Dauguet N; Dahou H; Baldan J; Libert M; Fain JS; Guerra C; Bouwens L; Barbacid M; Lemaigre FP; Jacquemin P
Cancer Res; 2021 May; 81(10):2679-2689. PubMed ID: 33602788
[TBL] [Abstract][Full Text] [Related]
19. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
[TBL] [Abstract][Full Text] [Related]
20. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
